Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Trimbow pMDI 87 micrograms/5 micrograms/9 micrograms pressurised inhalation, solution

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Beclometasone dipropionate, Formoterol fumarate dihydrate, Glycopyrronium bromide may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Beclometasone dipropionate, Formoterol fumarate dihydrate, Glycopyrronium bromide
Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for Trimbow is a medicine to help breathing that contains the three active substances:

  • beclometasone dipropionate,
  • formoterol fumarate dihydrate and
  • glycopyrronium.

•

if you have any disease of your liver or kidneys.

•

if you have diabetes. High doses of formoterol may increase your blood glucose and therefore you may need to have extra blood tests to check your blood sugar when you start using this medicine, and from time to time during treatment.

•

if you have a tumour of the adrenal gland (known as a phaeochromocytoma).

•

if you are due to have an anaesthetic. Depending on the type of anaesthetic, it may be necessary to stop using Trimbow at least 12 hours before the anaesthesia.

•

if you are being, or have ever been, treated for tuberculosis (TB) or if you have a chest infection.

•

if you have an eye problem called narrow-angle glaucoma.

•

if you have difficulty passing urine.

•

if you have an infection of the mouth or throat.

Beclometasone dipropionate belongs to a group of medicines called corticosteroids which act to reduce the swelling and irritation in your lungs. Formoterol and glycopyrronium are medicines called longacting bronchodilators. They act in different ways to relax the muscles in your airways, helping to open the airways wider and allowing you to breathe more easily. Regular treatment with these three active substances helps to relieve and prevent symptoms such as shortness of breath, wheezing and cough in adult patients with obstructive lung disease. Trimbow is used for the regular treatment of

  • chronic obstructive pulmonary disease (COPD) in adults
  • asthma in adults. Trimbow can reduce exacerbations (flare-ups) of COPD and asthma symptoms. COPD is a serious long-term disease in which the airways become blocked and air sacs inside the lungs become damaged, leading to difficulty breathing. Asthma is a serious, long-term disease where the muscles surrounding the airways become tight (bronchoconstriction) and swollen and irritated (inflammation). Symptoms come and go and include shortness of breath, wheezing, chest tightness and cough.

If any of the above applies to you, tell your doctor before you use Trimbow. If you have or have had any medical problems or any allergies or if you are not sure if you can use Trimbow, talk to your doctor or pharmacist before using the inhaler.

If you are already using Trimbow

What you need to know before you take it

e Trimbow

If you are using Trimbow or high doses of other inhaled corticosteroids over long periods and you come into a situation of stress (e.g. being taken to hospital after an accident, having a serious injury or before an operation) you may need more of this medicine. In such a situation, your doctor may need to increase your dose of corticosteroids to cope with the stress and may prescribe them as tablets or injections. Contact your doctor if you experience blurred vision or other visual disturbances.

Do not use Trimbow

Children and adolescents

You should use Trimbow every day and not only when you have breathing problems or other symptoms of asthma. This will ensure that it controls your asthma properly. Do not use this medicine to relieve a sudden attack of breathlessness or wheezing.

Do not give this medicine to children and adolescents below the age of 18 years.

If you are allergic to beclometasone dipropionate, formoterol fumarate dihydrate and/or glycopyrronium or any of the other ingredients of this medicine (listed in section 6).

Other medicines and Trimbow

Warnings and precautions

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines similar to Trimbow used for your lung disease.

If your breathing gets worse

Some medicines may increase the effects of Trimbow and your doctor may wish to monitor you carefully if you are taking these medicines (including some medicines for HIV: ritonavir, cobicistat).

Trimbow is used as a maintenance treatment for your obstructive lung disease. Do not use this medicine to treat a sudden attack of breathlessness or wheezing. If you develop worsening shortness of breath or wheezing (breathing with a whistling sound), straight after inhaling your medicine, stop using Trimbow inhaler and use your quick-acting "reliever" inhaler straightaway. You should contact your doctor straightaway. Your doctor will assess your symptoms and if necessary may start you on a different treatment. See also section 4, "Possible side effects".

If your lung disease gets worse

If your symptoms get worse or are difficult to control (e.g. if you are using a separate "reliever" inhaler more frequently) or if your "reliever" inhaler does not improve your symptoms, see your doctor immediately. Your lung disease may be getting worse and your doctor may need to prescribe different treatment.

Do not use this medicine with a beta-blocker medicine (used for treating certain heart problems such as angina or for reducing blood pressure) unless your doctor has chosen a beta-blocker that does not affect your breathing. Beta-blockers (including beta-blocker eye-drops) may reduce the effects of formoterol or make it not work at all. On the other hand, using other beta2-agonist medicines (which work in the same way as formoterol) may increase the effects of formoterol.

Using Trimbow together with: •

Talk to your doctor or pharmacist before using Trimbow •

if you have any heart problems, such as angina (heart pain, pain in the chest), a recent heart attack PAG. 1/4

medicines for treating

  • abnormal heart rhythms (quinidine, disopyramide, procainamide),
  • allergic reactions (antihistamines),
  • symptoms of depression or mental disorders such as monoamine oxidase inhibitors (for example phenelzine and isocarboxazid), tricyclic Chiesi Item

PAG. 1/4

CHIESI FARMACEUTICI S.p.A. – Parma – Italy NOT TO TAMPER THIS DOCUMENT

Artwork Owner: MS- mail: [email protected] MATERIAL TIPE: DESCRIPTION OF MATERIAL: FORMAT: DIMENSIONS mm: FONT AND min. SIZE:

DATAMATRIX CODE:

The laetus or datamatrix code assigned in the Datamatrix Laetus code production code will be used to avoid the mix-up code is dummy is dummy Black + halft 50%

1 l et 4 af 4 / Le ag. CK) P BA (

COLOUR PRINT N. 1:

Leaflet 1 Pag. 1/4 (FRONT)

4 2/ g. Pa ) t 1 CK fle (BA

or

Area with glue: max 5 mm

a Le

LAETUS CODE:

MOCK-UP FOR SUBMISSION LEAFLET TRIMBOW pMDI 87/5/9 mcg 120d UK F109 BACK 180 x 370 (after folding 180 x 38) Ubuntu, 8 pt

DIECUT

Reason of the change: NEW MOCK-UP FOR Windsor Framework changes

Leaflet 1 Pag. 3/4 (FRONT)

FOLD EXAMPLE

Text received on 16/04/2024 From: Darr K. CHECK BY Name:

Date:

PROOF N. /

1

DATE

FROM: /CHANGE FOR

30/04/24 Start activity

antidepressants (for example amitriptyline and imipramine), phenothiazines can cause some changes in the electrocardiogram (ECG, heart trace). They may also increase the risk of disturbances of heart rhythm (ventricular arrhythmias).

indicator to count down.

Testing your inhaler

•

medicines for treating Parkinson's disease (levodopa), to treat an underactive thyroid gland (levothyroxine), medicines containing oxytocin (which causes uterine contraction) and alcohol can increase the chances of formoterol side effects on the heart.

•

monoamine oxidase inhibitors (MAOIs), including medicines with similar properties like furazolidone and procarbazine, used to treat mental disorders, can cause a rise in blood pressure.

•

medicines for treating heart disease (digoxin) can cause a fall in your blood potassium level. This may increase the likelihood of abnormal heart rhythms.

•

other medicines used to treat obstructive lung disease (theophylline, aminophylline or corticosteroids) and diuretics may also cause a fall in your potassium level.

•

some anaesthetics can increase the risk of abnormal heart rhythms.

•

Disulfiram, a medicine used in the treatment of people with alcoholism (drinking problems) or metronidazole, an antibiotic to treat infection in your body can cause side effects (e.g. feeling sick, being sick, stomach pain) due to the small amount of alcohol in Trimbow.

Before using the inhaler for the first time, you should test your inhaler to make sure that it is working properly, as follows. 1. Depending on the container size prescribed to you, check that the dose counter reads 61 or 121 and that the dose indicator reads 180 2. Remove the protective cap from the mouthpiece 3. Hold your inhaler upright with the mouthpiece at the bottom 4. Direct the mouthpiece away from yourself and firmly press the pressurised container to release one puff 5. Check the dose counter or dose indicator. If you are testing your inhaler for the first time, the counter should read: 60

  • when using the container providing 60 puffs

120

  • when using the container providing 120 puffs

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine. You should only use Trimbow during pregnancy if you are advised to do so by your doctor. It is preferable to avoid the use of Trimbow during labour due to the inhibitory effects of formoterol on uterine contractions. You should not use Trimbow during breast-feeding. You and your doctor must make a decision whether to discontinue breast-feeding or to discontinue/abstain from Trimbow therapy taking into account the benefit of breastfeeding for your child and the benefit of therapy for you.

180

  • when using the container providing 180 puffs

How to use your inhaler

Stand or sit up when inhaling. IMPORTANT: Do not perform steps 2 to 5 too quickly.

Driving and using machines

Trimbow is unlikely to affect your ability to drive and use machines.

Trimbow contains ethanol

Trimbow contains 8.856 mg of alcohol (ethanol) in each actuation, which is equivalent to 17.712 mg per dose of two actuations. The amount in two actuations of this medicine is equivalent to less than 1 ml of wine or beer. The small amount of alcohol in this medicine will not have any noticeable effects.

How to take it

Trimbow Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. The recommended dose is two puffs in the morning and two puffs in the evening. Do not use more than your doctor tells you to use. You should use Trimbow every day, even when your asthma is not troubling you. Do not use this medicine to relieve a sudden attack of breathlessness or wheezing.

1. Remove the protective cap from the mouthpiece and check that the mouthpiece is clean and free from dust and dirt. 2. Breathe out as slowly and deeply as possible, in order to empty your lungs. 3. Hold the inhaler upright with the mouthpiece at the bottom and place the mouthpiece between your teeth without biting it. Then place your lips around the mouthpiece, with the tongue flat under it. 4. Breathe in slowly and deeply through your mouth to fill your lungs with air (this should take about 4-5 seconds). Just after starting to breathe in, press down firmly on the top of the pressurised container to release one puff. 5. Hold your breath for as long as possible and, finally, remove the inhaler from your mouth and breathe out slowly. Do not breathe out into the inhaler. 6. Check that the dose counter (60/120 puffs) has moved down by one or that the dose indicator (180 puffs) has rotated by a small amount.

If you feel that the medicine is not very effective, talk to your doctor. If you have been using a different inhaler containing beclometasone dipropionate previously, ask your doctor for advice, as the effective dose of beclometasone dipropionate in Trimbow for the treatment of your obstructive lung disease may be lower than that of some other inhalers.

Route of administration

Trimbow is for inhalation use. You should inhale the medicine through your mouth and this takes the medicine directly into your lungs. This medicine is contained in a pressurised container in a plastic inhaler with a mouthpiece.

For the second puff, keep the inhaler in the upright position for about half a minute, then repeat steps 2 to 5.

Trimbow is available in three container sizes:

  • a container providing 60 puffs
  • a container providing 120 puffs
  • a container providing 180 puffs.

If you see 'mist' coming from the top of the inhaler or the sides of your mouth, this means that Trimbow will not be getting into your lungs as it should. Take another puff, following the instructions starting again from step 2.

If you have been prescribed a container providing 60 puffs or 120 puffs

There is a counter on the back of the inhaler, which tells you how many doses are left. Each time you press the pressurised container, a puff of medicine is released and the counter will count down by one. Take care not to drop the inhaler as this may cause the counter to count down.

After use, replace the protective cap.

If you have been prescribed a container providing 180 puffs

When to get a new inhaler

There is an indicator on the back of the inhaler, which tells you how many doses are left. Each time you press the pressurised container, a puff of medicine is released and the dose indicator rotates by a small amount. The number of puffs remaining is displayed in intervals of 20. Take care not to drop the inhaler as this may cause the dose

To prevent a fungal infection in the mouth and throat, rinse your mouth or gargle with water without swallowing it or brush your teeth after each use of your inhaler. You should get a replacement when the counter or indicator shows the number 20. Stop using the inhaler when the counter or indicator shows 0, as any medicine left in the inhaler may not be enough to give you a full puff. If you have a weak grip, it may be easier to hold the inhaler

PAG. 2/4

Chiesi Item

PAG. 2/4

CHIESI FARMACEUTICI S.p.A. – Parma – Italy NOT TO TAMPER THIS DOCUMENT

Artwork Owner: MS- mail: [email protected] MATERIAL TIPE: DESCRIPTION OF MATERIAL: FORMAT: DIMENSIONS mm: FONT AND min. SIZE:

DATAMATRIX CODE:

The laetus or datamatrix code assigned in the Datamatrix Laetus code production code will be used to avoid the mix-up code is dummy is dummy Black + halft 50%

1 l et 4 af 4 / Le ag. CK) P BA (

COLOUR PRINT N. 1:

Leaflet 1 Pag. 1/4 (FRONT)

4 2/ g. Pa ) t 1 CK fle (BA

or

Area with glue: max 5 mm

a Le

LAETUS CODE:

MOCK-UP FOR SUBMISSION LEAFLET TRIMBOW pMDI 87/5/9 mcg 120d UK F109 FRONT 180 x 370 (after folding 180 x 38) Ubuntu, 8 pt

DIECUT

Reason of the change: NEW MOCK-UP FOR Windsor Framework changes

Leaflet 1 Pag. 3/4 (FRONT)

FOLD EXAMPLE

Text received on 16/04/2024 From: Darr K. CHECK BY Name:

Date:

PROOF N. /

1

DATE

FROM: /CHANGE FOR

30/04/24 Start activity

with both hands: hold the upper part of the inhaler with both index fingers and its lower part with both thumbs.

• • • • • • • • • • • • • •

If you find it difficult to use the inhaler while starting to breathe in, you may use the AeroChamber Plus spacer device. Ask your doctor or pharmacist about this device. It is important that you read the package leaflet which is supplied with your AeroChamber Plus spacer device and that you carefully follow the instructions on how to use the AeroChamber Plus spacer device and how to clean it.

Cleaning of the Trimbow inhaler

You should clean your inhaler once a week. 1. Do not remove the pressurised container from the inhaler and do not use water or other liquids to clean your inhaler. 2. Remove the protective cap from the mouthpiece by pulling it away from your inhaler. 3. Wipe inside and outside of the mouthpiece and the inhaler with a clean, dry cloth or tissue. 4. Replace the mouthpiece cap.

• • • • • • •

If you use more Trimbow than you should

It is important that you take your dose as advised by your doctor. Do not exceed your prescribed dose without talking to your doctor. If you use more Trimbow than you should, side effects, as described in section 4, may occur.

Tell your doctor if you have used more Trimbow than you should and if you experience any of these symptoms. Your doctor may wish to carry out some blood tests.

If you forget to use Trimbow

Use it as soon as you remember. If it is almost time for your next dose, do not take the dose you have missed, but just take the next dose at the correct time. Do not double the dose.

If you stop using Trimbow

It is important to use Trimbow every day. Do not stop using Trimbow or lower the dose, even if you are feeling better or you have no symptoms. If you want to do this, talk to your doctor. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

•

cough and productive cough irritation of the throat nose bleeds redness of the pharynx dry mouth diarrhoea swallowing difficulties feeling sick upset stomach stomach discomfort after meals burning sensation of the lips tooth decay skin rash, hives, skin itching inflammation of the mucous membrane of the mouth with or without ulcers increased sweating muscle cramps and pain in muscles pain in arms or legs pain in muscles, bones or joints of the chest tiredness increase of blood pressure fall in the level of some constituents of your blood: of certain white blood cells called granulocytes, of potassium or of cortisol increase in the level of some constituents of your blood: glucose, C-reactive protein, number of platelets, insulin, free fatty acid or ketones.

Rare (may affect up to 1 in 1,000 people):

  • fungal infections of the chest
  • decreased appetite
  • sleep disorders (sleeping too little or too long)
  • crushing chest pain
  • sensation of a missed heart beat or of extra heart beats, unusually slow heart beat
  • worsening of asthma
  • leakage of blood from a vessel into the tissues surrounding it
  • decrease of blood pressure
  • pain in the back of the mouth and throat
  • weakness
  • inflammation of the pharynx
  • dry throat
  • painful and frequent urination
  • difficulty and pain when passing urine
  • inflammation of the kidneys. Very rare (may affect up to 1 in 10,000 people):
  • low level in the number of certain blood cells called platelets
  • feeling breathless or short of breath
  • swelling of the hands and feet
  • growth retardation in children and adolescents.

4. Possible side effects Like all medicines, this medicine can cause side effects, although not everybody gets them. There is a risk of worsening shortness of breath and wheezing immediately after using Trimbow and this is known as paradoxical bronchospasm (may affect up to 1 in 1,000 people). If this occurs you should stop using Trimbow and use your quick-acting "reliever" inhaler straightaway to treat the shortness of breath and wheezing. You should contact your doctor straightaway.

Not known (frequency cannot be estimated from the available data):

  • blurred vision

Tell your doctor immediately

  • if you experience any allergic reactions like skin allergies, hives, skin itching, skin rash (may affect up to 1 in 100 people), reddening of the skin, swelling of the skin or mucous membranes especially of the eyes, face, lips and throat (may affect up to 1 in 1,000 people).
  • if you experience eye pain or discomfort, temporary blurring of vision, visual halos or coloured images in association with red eyes. These may be signs of an acute attack of narrow-angle glaucoma (may affect up to 1 in 10,000 people).

•

Using high-dose inhaled corticosteroids over a long time can cause in very rare cases effects on the body:

Tell your doctor if you have any of the following while using Trimbow as they could be symptoms of a lung infection (may affect up to 1 in 10 people):

  • fever or chills
  • increased mucus production, change in mucus colour
  • increased cough or increased breathing difficulties.

• •

problems with how your adrenal glands work (adrenal suppression) decrease in bone mineral density (thinning of the bones) clouding of the lens of your eyes (cataract).

Trimbow does not contain a high-dose inhaled corticosteroid, but your doctor may wish to measure the cortisol levels in your blood from time to time. The following side effects can also occur with high-dose inhaled corticosteroids used over a long time, but the frequency is not known (frequency cannot be estimated from the available data) at present:

  • depression
  • feeling worried, nervous, over-excited or irritable. These events are more likely to occur in children.

Reporting of side effects

Possible side effects are listed below according to their frequency. Common (may affect up to 1 in 10 people):

  • sore throat
  • runny or stuffy nose and sneezing
  • fungal infections of the mouth. Rinsing your mouth or gargling with water and brushing your teeth immediately after inhalation may help to prevent these

Possible side effects

  • hoarseness
  • headache
  • urinary tract infection. Uncommon (may affect up to 1 in 100 people):
  • flu
  • inflammation of the sinuses
  • itchy, runny or blocked nose
  • fungal infections of the throat or of the food pipe (oesophagus)
  • fungal infections of the vagina
  • restlessness
  • trembling
  • dizziness
  • abnormal or reduced sense of taste
  • numbness
  • inflammation of the ear
  • irregular heart beat
  • changes in the electrocardiogram (heart trace)
  • unusually fast heart beat and disorders of the heart rhythm
  • palpitations (feeling of abnormal beating of the heart)
  • reddening of the face
  • increased blood flow to some tissues in the body
  • asthma attack

If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via: Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store By reporting side effects you can help provide more information on the safety of this medicine.

How to store it

Trimbow Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date refers to the last day of that month. Do not freeze. Do not expose to temperatures higher than 50°C. Do not pierce the pressurised container. Prior to dispensing: Store in a refrigerator (2°C‐8°C). After dispensing (receiving this medicine from your pharmacist): 60 actuation pressurised container: Store the inhaler below 25°C for a maximum of 2 months. 120 (from a single or multipack) and 180 actuation pressurised container: Store the inhaler below 25°C for a maximum of 4 months. Do not throw away any medicines via waste-water or household waste. Ask your pharmacist how to throw away

PAG. 3/4

Chiesi Item

PAG. 3/4

CHIESI FARMACEUTICI S.p.A. – Parma – Italy NOT TO TAMPER THIS DOCUMENT

Artwork Owner: MS- mail: [email protected] MATERIAL TIPE: DESCRIPTION OF MATERIAL: FORMAT: DIMENSIONS mm: FONT AND min. SIZE: LAETUS CODE:

MOCK-UP FOR SUBMISSION LEAFLET TRIMBOW pMDI 87/5/9 mcg 120d UK F109 BACK 180 x 370 (after folding 180 x 38) Ubuntu, 8 pt

Area with glue: max 5 mm

Leaflet 1 Pag. 1/4 (FRONT)

DIECUT

1 l et 4 af 4 / Le ag. CK) P BA (

Black + halft 50%

COLOUR PRINT N. 1:

4 2/ g. Pa ) t 1 CK fle (BA

DATAMATRIX CODE:

a Le

The laetus or datamatrix code assigned in the Datamatrix Laetus code production code will be used to avoid the mix-up code is dummy is dummy

or

Reason of the change: NEW MOCK-UP FOR Windsor Framework changes

Leaflet 1 Pag. 3/4 (FRONT)

FOLD EXAMPLE

Text received on 16/04/2024 From: Darr K. CHECK BY Name:

Date:

PROOF N. /

1

DATE

FROM: /CHANGE FOR

30/04/24 Start activity

medicines you no longer use. These measures will help protect the environment.

6. Content of the pack and other information What Trimbow contains

The active substances are: beclometasone dipropionate, formoterol fumarate dihydrate and glycopyrronium. Each delivered dose (the dose leaving the mouthpiece) contains 87 micrograms of beclometasone dipropionate, 5 micrograms of formoterol fumarate dihydrate and 9 micrograms of glycopyrronium (as 11 micrograms glycopyrronium bromide). Each metered dose (the dose leaving the valve) contains 100 micrograms of beclometasone dipropionate, 6 micrograms of formoterol fumarate dihydrate and 10 micrograms of glycopyrronium (as 12.5 micrograms of glycopyrronium bromide). The other ingredients are: ethanol anhydrous (see section 2), hydrochloric acid, propellant: norflurane.

What Trimbow looks like and contents of the pack Trimbow is a pressurised inhalation, solution. Trimbow comes in a pressurised container (coated

aluminium), with a metering valve. The pressurised container is inserted in a plastic inhaler. This incorporates a mouthpiece provided with a plastic protective cap, and either a dose counter (containers with 60 and 120 puffs) or a dose indicator (containers with 180 puffs). Each pack contains one pressurised container either providing 60 puffs, 120 puffs or 180 puffs. Additionally there are multipacks containing either 240 puffs (2 pressurised containers with 120 puffs, each) or 360 puffs (3 pressurised containers with 120 puffs, each). Not all pack sizes may be marketed.

Marketing Authorisation Holder Chiesi Limited 333 Styal Road Manchester M22 5LG UK

Manufacturers

Chiesi Farmaceutici S.p.A. Via San Leonardo 96 43122 Parma Italy Chiesi SAS 2 rue des Docteurs Alberto et Paolo Chiesi 41260 La Chaussée Saint Victor France Chiesi Pharmaceuticals GmbH Gonzagagasse 16/16 1010 Wien Austria This leaflet was last revised in June 2024 Is this leaflet hard to see or read? Phone 0161 488 5555 for help.

CP0061/6

PAG. 4/4

Chiesi Item

PAG. 4/4

Contents of the pack and other information

(myocardial infarction), heart failure, narrowing of the arteries around your heart (coronary heart disease), disease of your heart valves or any other abnormalities of your heart or if you have a condition known as hypertrophic obstructive cardiomyopathy (also known as HOCM, a condition where the heart muscle is abnormal). •

if you have disorders of your heart rhythm such as irregular heart rate, a fast pulse rate or palpitations or if you have been told that your heart trace (ECG) is abnormal.

•

if you have narrowing of the arteries (also known as arteriosclerosis), if you have high blood pressure or if you have an aneurysm (abnormal bulging of the blood vessel wall). if you have an overactive thyroid gland. if you have low blood levels of potassium (hypokalaemia). The combination of Trimbow with some other lung medicines or medicines such as diuretics (medicines that make the body lose water, to treat heart disease or high blood pressure), can cause a sharp fall in your blood level of potassium. Therefore, your doctor may wish to measure the potassium levels in your blood from time to time.

• •

Frequently asked questions about Trimbow pMDI 87 micrograms/5 micrograms/9 micrograms pressurised inhalation, solution

How do I take Trimbow pMDI 87 micrograms/5 micrograms/9 micrograms pressurised inhalation, solution?

Trimbow pMDI 87 micrograms/5 micrograms/9 micrograms pressurised inhalation, solution comes as inhaler containing 87mcg / 5mcg / 9mcg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Trimbow pMDI 87 micrograms/5 micrograms/9 micrograms pressurised inhalation, solution?

The active substance in Trimbow pMDI 87 micrograms/5 micrograms/9 micrograms pressurised inhalation, solution is beclometasone dipropionate, formoterol fumarate dihydrate, glycopyrronium bromide.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Trimbow pMDI 87 micrograms/5 micrograms/9 micrograms pressurised inhalation, solution, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Trimbow pMDI 87 micrograms/5 micrograms/9 micrograms pressurised inhalation, solution without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

  • Source: electronic medicines compendium (emc), Datapharm
  • Active substance: beclometasone dipropionate, formoterol fumarate dihydrate, glycopyrronium bromide
  • Official document: view the original leaflet on emc →
Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Beclometasone dipropionate (44 medicines), Beclometasone dipropionate, formoterol fumarate dihydrate, glycopyrronium bromide (3 medicines), Formoterol fumarate dihydrate (37 medicines), Glycopyrronium bromide (30 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

Chronic obstructive pulmonary disease (COPD)

Maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or a combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.1).

Asthma

Maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.

4.2. Posology and method of administration

Posology

The recommended dose is two inhalations twice daily.

The maximum dose is two inhalations twice daily.

Patients should be advised to take Trimbow every day even when asymptomatic.

If symptoms arise in the period between doses, an inhaled, short-acting beta2-agonist should be used for immediate relief.

Asthma

When choosing the starting dose strength of Trimbow (87/5/9 micrograms or 172/5/9 micrograms), the patients' disease severity, their previous asthma therapy including the inhaled corticosteroid (ICS) dose as well as the patients' current control of asthma symptoms and risk of future exacerbation should be considered.

Stepping-down treatment

Patients should be regularly reassessed by a doctor, so that their doses of beclometasone/formoterol/glycopyrronium remain optimal and are only changed on medical advice. The doses should be titrated to the lowest doses at which effective control of asthma symptoms is maintained.

Special populations

Elderly

No dose adjustment is required in elderly patients (65 years of age and older).

Renal impairment

Trimbow can be used at the recommended dose in patients with mild (glomerular filtration rate [GFR] ≥50 to <80 mL/min/1.73 m2) to moderate (GFR ≥30 to <50 mL/min/1.73 m2) renal impairment. Use in patients with severe (GFR <30 mL/min/1.73 m2) renal impairment or end-stage renal (GFR <15 mL/min/1.73 m2) disease requiring dialysis, especially if associated with significant body weight reduction, should be considered only if the expected benefit outweighs the potential risk (see sections 4.4 and 5.2).

Hepatic impairment

There are no relevant data on the use of Trimbow in patients with severe hepatic impairment (classified as having Child-Pugh class C) and the medicinal product should be used with caution in these patients (see sections 4.4 and 5.2).

Paediatric population

COPD

There is no relevant use of Trimbow in the paediatric population (under 18 years of age) for the indication of COPD.

Asthma

The safety and efficacy of Trimbow in the paediatric population (under 18 years of age) have not yet been established. No data are available.

Method of administration

For inhalation use.

To ensure proper administration of the medicinal product, the patient should be shown how to use the inhaler correctly by a physician or other healthcare professional, who should also regularly check the adequacy of the patient's inhalation technique (see “Instructions for use” below). The patient should be advised to read the Package Leaflet carefully and follow the instructions for use as given in the leaflet.

This medicinal product is provided with a dose counter or dose indicator on the back of the inhaler, which shows how many actuations are left. For the 60 and 120 actuation pressurised containers, each time the patient presses the container a puff of the solution is released and the counter counts down by one.

For the 180 actuation pressurised container, each time the patient presses the pressurised container a puff of the solution is released and the indicator rotates by a small amount; the number of puffs remaining is displayed in intervals of 20.

The patient should be advised not to drop the inhaler as this may cause the counter to count down.

Instructions for use

Priming the inhaler

Before using the inhaler for the first time, the patient should release one actuation into the air in order to ensure that the inhaler is working properly (priming). Before priming the 60, 120 or 180 actuation pressurised containers, the counter/indicator should read 61, 121 or 180, respectively. After priming, the counter/indicator should read 60, 120 or 180.

Use of the inhaler

The patient should stand or sit in an upright position when inhaling from the inhaler. The steps below should be followed.

IMPORTANT: steps 2 to 5 should not be performed too quickly:

1. The patient should remove the protective cap from the mouthpiece and check that the mouthpiece is clean and free from dust and dirt or any other foreign objects.

2. The patient should breathe out slowly and as deeply as comfortable, in order to empty the lungs.

3. The patient should hold the inhaler vertically with its body upwards and place the mouthpiece between the teeth without biting. The lips should then be placed around the mouthpiece, with the tongue flat under it.

4. At the same time, the patient should breathe in slowly and deeply through the mouth until the lungs are full of air (this should take approximately 4 – 5 seconds). Immediately after starting to breathe in, the patient should firmly press down on the top of the pressurised container to release one puff.

5. The patient should then hold their breath for as long as comfortably possible, then remove the inhaler from the mouth and breathe out slowly. The patient should not breathe out into the inhaler.

6. The patient should then check the dose counter or dose indicator to ensure it has moved accordingly.

To inhale the second puff, the patient should keep the inhaler in a vertical position for approximately 30 seconds and repeat steps 2 to 6.

If mist appears after the inhalation, either from the inhaler or from the sides of the mouth, the procedure should be repeated from step 2.

After use, the patient should close the inhaler with the protective mouthpiece cap and check the dose counter or dose indicator.

After inhaling, the patient should rinse the mouth or gargle with water without swallowing it or brush the teeth (see also section 4.4).

When to get a new inhaler

The patient should be advised to get a new inhaler when the dose counter or indicator shows the number 20. He/she should stop using the inhaler when the counter or indicator shows 0 as any puffs left in the device may not be enough to release a full actuation.

Additional instructions for specific groups of patients

For patients with weak hands it may be easier to hold the inhaler with both hands. Therefore, the index fingers should be placed on the top of the pressurised container and both thumbs on the base of the inhaler.

Patients who find it difficult to synchronise aerosol actuation with inspiration of breath may use the AeroChamber Plus spacer device, properly cleaned as described in the relevant leaflet. They should be advised by their doctor or pharmacist about the proper use and care of their inhaler and spacer and their technique checked to ensure optimum delivery of the inhaled active substance to the lungs. This may be obtained by the patients using the AeroChamber Plus by one continuous slow and deep breath through the spacer, without any delay between actuation and inhalation. Alternatively, patients may simply breathe in and out (through the mouth) after the actuation, as instructed in the spacer leaflet, to obtain the medicinal product (see sections 4.4 and 5.2).

Cleaning

For the regular cleaning of the inhaler, patients should remove weekly the cap from the mouthpiece and wipe the outside and inside of the mouthpiece with a dry cloth. They should not remove the pressurised container from the actuator and should not use water or other liquids to clean the mouthpiece.

4.3. Contraindications

Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.

4.4. Special warnings and precautions for use

Not for acute use

This medicinal product is not indicated for the treatment of acute episodes of bronchospasm, or to treat an acute disease exacerbation (i.e. as a rescue therapy).

Hypersensitivity

Immediate hypersensitivity reactions have been reported after administration. If signs suggesting allergic reactions occur, in particular, angioedema (including difficulties in breathing or swallowing, swelling of the tongue, lips and face), urticaria or skin rash, treatment should be discontinued immediately and alternative therapy instituted.

Paradoxical bronchospasm

Paradoxical bronchospasm may occur with an immediate increase in wheezing and shortness of breath after dosing. This should be treated immediately with a fast-acting inhaled bronchodilator (reliever). Treatment should be discontinued immediately, the patient assessed and alternative therapy instituted if necessary.

Deterioration of disease

It is recommended that treatment should not be stopped abruptly. If patients find the treatment ineffective, they should continue treatment but medical attention must be sought. Increasing use of reliever bronchodilators indicates a worsening of the underlying condition and warrants a reassessment of the therapy. Sudden or progressive deterioration in symptoms is potentially life-threatening and the patient should undergo urgent medical assessment.

Cardiovascular effects

Due to the presence of a long-acting beta2-agonist and a long-acting muscarinic antagonist, Trimbow should be used with caution in patients with cardiac arrhythmias, especially third degree atrioventricular block and tachyarrhythmias (accelerated and/or irregular heartbeat, including atrial fibrillation), idiopathic subvalvular aortic stenosis, hypertrophic obstructive cardiomyopathy, severe heart disease (particularly acute myocardial infarction, ischaemic heart disease, congestive heart failure), occlusive vascular diseases (particularly arteriosclerosis), arterial hypertension and aneurysm.

Caution should also be exercised when treating patients with known or suspected prolongation of the QTc interval (QTc > 450 milliseconds for males, or > 470 milliseconds for females), either congenital or induced by medicinal products. Patients diagnosed with the described cardiovascular conditions were excluded from clinical studies with Trimbow. Limited data in asthmatic patients with cardiovascular co-morbidities or risk-factors suggest that these patients are also at higher risk of adverse reactions like local fungal infections or dysphonia (see section 4.8).

If anaesthesia with halogenated anaesthetics is planned, it should be ensured that Trimbow is not administered for at least 12 hours before the start of anaesthesia as there is a risk of cardiac arrhythmias.

Caution is also required when treating patients with thyrotoxicosis, diabetes mellitus, pheochromocytoma and untreated hypokalaemia.

Pneumonia in patients with COPD

An increase in the incidence of pneumonia, including pneumonia requiring hospitalisation, has been observed in patients with COPD receiving inhaled corticosteroids. There is some evidence of an increased risk of pneumonia with increasing steroid dose but this has not been demonstrated conclusively across all studies.

There is no conclusive clinical evidence for intra-class differences in the magnitude of the pneumonia risk among inhaled corticosteroid products.

Physicians should remain vigilant for the possible development of pneumonia in patients with COPD as the clinical features of such infections overlap with the symptoms of COPD exacerbations.

Risk factors for pneumonia in patients with COPD include current smoking, older age, low body mass index (BMI) and severe COPD.

Systemic corticosteroid effects

Systemic effects may occur with any inhaled corticosteroid, particularly at high doses prescribed for long periods. The daily dose of Trimbow corresponds to a medium dose of inhaled corticosteroid; furthermore, these effects are much less likely to occur than with oral corticosteroids. Possible systemic effects include: Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation, decrease in bone mineral density and, more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children). Therefore, it is important that the patient is reviewed regularly, and the dose of inhaled corticosteroid is reduced to the lowest dose at which effective control of asthma is maintained (see section 4.2).

Trimbow should be administered with caution in patients with active or quiescent pulmonary tuberculosis and in patients with fungal and viral infections in the airways.

Hypokalaemia

Potentially serious hypokalaemia may result from beta2-agonist therapy. This has the potential to produce adverse cardiovascular effects. Particular caution is advised in patients with severe disease as this effect may be potentiated by hypoxia. Hypokalaemia may also be potentiated by concomitant treatment with other medicinal products which can induce hypokalaemia, such as xanthine derivatives, steroids and diuretics (see section 4.5).

Caution is also recommended when a number of reliever bronchodilators are used. It is recommended that serum potassium levels are monitored in such situations.

Hyperglycaemia

The inhalation of formoterol may cause a rise in blood glucose levels. Therefore, blood glucose should be monitored during treatment following established guidelines in patients with diabetes.

Anticholinergic effect

Glycopyrronium should be used with caution in patients with narrow-angle glaucoma, prostatic hyperplasia or urinary retention. Patients should be informed about the signs and symptoms of acute narrow-angle glaucoma and should be informed to stop treatment and to contact their doctor immediately should any of these signs or symptoms develop.

Additionally, due to the anticholinergic effect of glycopyrronium, the long-term co-administration with other anticholinergic-containing medicinal products is not recommended (see section 4.5).

Patients with severe renal impairment

In patients with severe renal impairment, including those with end-stage renal disease requiring dialysis, especially if associated with a significant body weight reduction, Trimbow should be used only if the expected benefit outweighs the potential risk (see section 5.2). These patients should be monitored for potential adverse reactions.

Patients with severe hepatic impairment

In patients with severe hepatic impairment, Trimbow should be used only if the expected benefit outweighs the potential risk (see section 5.2). These patients should be monitored for potential adverse reactions.

Prevention of oropharyngeal infections

In order to reduce the risk of oropharyngeal candida infection, patients should be advised to rinse their mouth or gargle with water without swallowing it or brush their teeth after inhaling the prescribed dose.

Visual disturbance

Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.

Stepping-down treatment

Patients should be regularly reassessed by a doctor, so that their doses of beclometasone/formoterol/glycopyrronium remain optimal and are only changed on medical advice. The doses should be titrated to the lowest doses at which effective control of asthma symptoms is maintained.

Ethanol contents

This medicinal product contains 8.856 mg of ethanol per actuation, which is equivalent to 17.712 mg per dose of two actuations. There is a theoretical potential for interaction in particularly sensitive patients taking disulfiram or metronidazole.

4.5. Interaction with other medicinal products and other forms of interaction

Pharmacokinetic interactions

Since glycopyrronium is eliminated mainly by the renal route, interaction could potentially occur with medicinal products affecting renal excretion mechanisms (see section 5.2). The effect of organic cation transport inhibition (using cimetidine as a probe inhibitor of OCT2 and MATE1 transporters) in the kidneys on inhaled glycopyrronium disposition showed a limited increase in its total systemic exposure (AUC0-t) by 16% and a slight decrease in renal clearance by 20% due to co administration of cimetidine.

Beclometasone is less dependent on CYP3A metabolism than some other corticosteroids, and in general interactions are unlikely; however, the possibility of systemic effects with concomitant use of strong CYP3A inhibitors (e.g. ritonavir, cobicistat) cannot be excluded, and therefore caution and appropriate monitoring is advised with the use of such medicinal products.

Pharmacodynamic interactions

Related to formoterol

Non-cardioselective beta-blockers (including eye drops) should be avoided in patients taking inhaled formoterol. If they are administered for compelling reasons, the effect of formoterol will be reduced or abolished.

Concomitant use of other beta-adrenergic medicinal products can have potentially additive effects; therefore, caution is required when other beta-adrenergic medicinal products are prescribed concomitantly with formoterol.

Concomitant treatment with quinidine, disopyramide, procainamide, antihistamines, monoamine oxidase inhibitors, tricyclic antidepressants and phenothiazines can prolong the QT interval and increase the risk of ventricular arrhythmias. In addition, L-dopa, L-thyroxine, oxytocin and alcohol can impair cardiac tolerance towards beta2-sympathomimetics.

Concomitant treatment with monoamine oxidase inhibitors, including medicinal products with similar properties such as furazolidone and procarbazine, may precipitate hypertensive reactions.

There is an elevated risk of arrhythmias in patients receiving concomitant anaesthesia with halogenated hydrocarbons.

Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalaemic effect of beta2-agonists (see section 4.4). Hypokalaemia may increase the disposition towards arrhythmias in patients who are treated with digitalis glycosides.

Related to glycopyrronium

The long-term co-administration of Trimbow with other anticholinergic-containing medicinal products has not been studied and is therefore not recommended (see section 4.4).

4.6. Fertility, pregnancy and lactation

There is no experience with or evidence of safety issues on the use of the propellant norflurane (HFA134a) during human pregnancy or lactation. However, studies on the effect of HFA134a on the reproductive function and embryofoetal development in animals revealed no clinically relevant adverse effects.

Pregnancy

There are no or limited amount of data from the use of Trimbow in pregnant women.

Studies in animals have shown reproductive toxicity (see section 5.3). Glucocorticoids are known to cause effects in the early gestation phase, while beta2-sympathomimetics like formoterol have tocolytic effects. Therefore, as a precautionary measure, it is preferable to avoid the use of Trimbow during pregnancy and during labour.

Trimbow should only be used during pregnancy if the expected benefit to the patient outweighs the potential risk to the foetus. Infants and neonates born to mothers receiving substantial doses should be observed for adrenal suppression.

Breast-feeding

There are no relevant clinical data on the use of Trimbow during breast-feeding in humans.

Glucocorticoids are excreted in human milk. It is reasonable to assume that beclometasone dipropionate and its metabolites are also excreted in human milk.

It is unknown whether formoterol or glycopyrronium (including their metabolites) are excreted in human milk but they have been detected in the milk of lactating animals. Anticholinergics like glycopyrronium could suppress lactation.

A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Trimbow therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.

Fertility

No specific studies have been performed with Trimbow with regard to the safety in human fertility. Animal studies have shown impairment of fertility (see section 5.3).

4.7. Effects on ability to drive and use machines

Trimbow has no or negligible influence on the ability to drive and use machines.

4.8. Undesirable effects

Summary of the safety profile

The most frequently reported adverse reactions in patients with COPD or asthma are respectively: dysphonia (0.3% and 1.5%) and oral candidiasis (0.8% and 0.3%), which are normally associated with inhaled corticosteroids; muscle spasms (0.4% and 0.2%), which can be attributed to the long-acting beta2-agonist component; and dry mouth (0.4% and 0.5%), which is a typical anticholinergic effect.

In asthmatic patients, adverse reactions tend to cluster during the first 3 months following initiation of therapy and become less frequent with longer-term use (after 6 months of treatment).

Tabulated list of adverse reactions

Adverse reactions associated to beclometasone dipropionate/formoterol/glycopyrronium occurred during clinical studies and post-marketing experience as well as adverse reactions listed for the marketed individual components are provided below, listed by system organ class and frequency.

Frequencies are defined as: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000) and not known (cannot be estimated from available data).

MedDRA system organ class

Adverse reaction

Frequency

Infections and infestations

Pneumonia (in COPD patients), pharyngitis, oral candidiasis, urinary tract infection1, nasopharyngitis1

Common

Influenza1, oral fungal infection, oropharyngeal candidiasis, oesophageal candidiasis, fungal (oro)pharyngitis, sinusitis1, rhinitis1, gastroenteritis1, vulvovaginal candidiasis1

Uncommon

Lower respiratory tract infection (fungal)

Rare

Blood and lymphatic system disorders

Granulocytopenia1

Uncommon

Thrombocytopenia1

Very rare

Immune system disorders

Dermatitis allergic1

Uncommon

Hypersensitivity reactions, including erythema, lips, face, eye and pharyngeal oedema

Rare

Endocrine disorders

Adrenal suppression1

Very rare

Metabolism and nutrition disorders

Hypokalaemia, hyperglycaemia

Uncommon

Decreased appetite

Rare

Psychiatric disorders

Restlessness1

Uncommon

Psychomotor hyperactivity1, sleep disorders1, anxiety, depression1, aggression1, behavioural changes (predominantly in children) 1

Frequency not known

Insomnia

Rare

Nervous system disorders

Headache

Common

Tremor, dizziness, dysgeusia1, hypoaesthesia1

Uncommon

Hypersomnia

Rare

Eye disorders

Vision, blurred1 (see also section 4.4)

Frequency not known

Glaucoma1, cataract1

Very rare

Ear and labyrinth disorders

Otosalpingitis1

Uncommon

Cardiac disorders

Atrial fibrillation, electrocardiogram QT prolonged, tachycardia, tachyarrhythmia1, palpitations

Uncommon

Angina pectoris (stable1 and unstable), extrasystoles (ventricular1 and supraventricular), nodal rhythm, sinus bradycardia

Rare

Vascular disorders

Hyperaemia1, flushing1, hypertension

Uncommon

Extravasation blood

Rare

Respiratory, thoracic and mediastinal disorders

Dysphonia

Common

Asthmatic crisis1, cough, productive cough1, throat irritation, epistaxis1, pharyngeal erythema

Uncommon

Bronchospasm paradoxical1, exacerbation of asthma, oropharyngeal pain, pharyngeal inflammation, dry throat

Rare

Dyspnoea1

Very rare

Gastrointestinal disorders

Diarrhoea1, dry mouth, dysphagia1, nausea, dyspepsia1, burning sensation of the lips1, dental caries1, (aphthous) stomatitis

Uncommon

Skin and subcutaneous tissue disorders

Rash1, urticaria, pruritus, hyperhidrosis1

Uncommon

Angioedema1

Rare

Musculoskeletal and connective tissue disorders

Muscle spasms, myalgia, pain in extremity1, musculoskeletal chest pain1

Uncommon

Growth retardation1

Very rare

Renal and urinary disorders

Dysuria, urinary retention, nephritis1

Rare

General disorders and administration site conditions

Fatigue1

Uncommon

Asthenia

Rare

Oedema peripheral1

Very rare

Investigations

C-reactive protein increased1, platelet count increased1, free fatty acids increased1, blood insulin increased1, blood ketone body increased1, cortisol decreased1

Uncommon

Blood pressure increased1, blood pressure decreased1

Rare

Bone density decreased1

Very rare

1 Adverse reactions reported in the SmPC of at least one of the individual components, but not observed as adverse reactions in the clinical development of Trimbow

Among the observed adverse reactions the following are typically associated with:

Beclometasone dipropionate

Pneumonia, oral fungal infections, lower respiratory tract infection fungal, dysphonia, throat irritation, hyperglycaemia, psychiatric disorders, cortisol decreased, blurred vision.

Formoterol

Hypokalaemia, hyperglycaemia, tremor, palpitations, muscle spasms, electrocardiogram QT prolonged, blood pressure increased, blood pressure decreased, atrial fibrillation, tachycardia, tachyarrhythmia, angina pectoris (stable and unstable), ventricular extrasystoles, nodal rhythm.

Glycopyrronium

Glaucoma, atrial fibrillation, tachycardia, palpitations, dry mouth, dental caries, dysuria, urinary retention, urinary tract infection.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:

Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9. Overdose

An overdose of Trimbow may produce signs and symptoms due to the individual component's pharmacological actions, including those seen with overdose of other beta2-agonists or anticholinergics and consistent with the known inhaled corticosteroid class effects (see section 4.4). If overdose occurs, the patient's symptoms should be treated supportively with appropriate monitoring as necessary.

🇷🇴 Known in Romania as

Medicines sold in Romania with the same active substance: Cunoscut în România ca

⚠ Not the same combination. This medicine contains Beclometasone dipropionate, Formoterol fumarate dihydrate, Glycopyrronium bromide. The products below do not contain exactly the same set of active substances — they are not direct substitutes.

  • FOSTER NEXTHALER 100/6 micrograme pe doza prescription partial — not the same combinationCOMBINATII (BECLOMETASONUM+FORMOTEROLUM) · inhaler / nebuliser
  • BECLOMETAZONA /FORMOTEROL STADA 100/6 micrograme/pe doza prescription partial — not the same combinationCOMBINATII (BECLOMETASONUM+FORMOTEROLUM) · inhaler / nebuliser
  • BECLOMETAZONA /FORMOTEROL STADA 200/6 micrograme/pe doza prescription partial — not the same combinationCOMBINATII (BECLOMETASONUM+FORMOTEROLUM) · inhaler / nebuliser
  • BECLOMETAZONA/FORMOTEROL GENETIC 100 micrograme/6 micrograme pe doza prescription partial — not the same combinationCOMBINATII (BECLOMETASONUM+FORMOTEROLUM) · inhaler / nebuliser
  • BECLOMETAZONA/FORMOTEROL GENETIC 200 micrograme/6 micrograme pe doza prescription partial — not the same combinationCOMBINATII (BECLOMETASONUM+FORMOTEROLUM) · inhaler / nebuliser
  • FOSTER 200 micrograme/6 micrograme prescription partial — not the same combinationCOMBINATII (BECLOMETASONUM+FORMOTEROLUM) · inhaler / nebuliser

Some of these do not contain exactly the same active substances — check each one. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →

🇵🇱 Known in Poland as

Medicines sold in Poland with the same active substance: W Polsce znany jako

⚠ Not the same combination. This medicine contains Beclometasone dipropionate, Formoterol fumarate dihydrate, Glycopyrronium bromide. The products below do not contain exactly the same set of active substances — they are not direct substitutes.

  • Zafiron partial — not the same combinationFormoteroli fumaras · inhaler / nebuliser
  • Seebri Breezhaler partial — not the same combinationGlycopyrronii bromidum · inhaler / nebuliser
  • Enurev Breezhaler partial — not the same combinationGlycopyrronii bromidum · inhaler / nebuliser
  • Tovanor Breezhaler partial — not the same combinationGlycopyrronii bromidum · inhaler / nebuliser
  • AMIDIL AmiHaler partial — not the same combinationGlycopyrronii bromidum · inhaler / nebuliser
  • Trimbow partial — not the same combinationBeclometasoni dipropionas + Formoteroli fumaras dihydricus + Glycopyrronium · inhaler / nebuliser

Some of these do not contain exactly the same active substances — check each one. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →

💬 Ask about this leaflet

Ask anything about Trimbow pMDI 87 micrograms/5 micrograms/9 micrograms pressurised inhalation, solution. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →